These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 30679180)

  • 1. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
    Vuong L; Kouverianou E; Rooney CM; McHugh BJ; Howie SEM; Gregory CD; Forbes SJ; Henderson NC; Zetterberg FR; Nilsson UJ; Leffler H; Ford P; Pedersen A; Gravelle L; Tantawi S; Schambye H; Sethi T; MacKinnon AC
    Cancer Res; 2019 Apr; 79(7):1480-1492. PubMed ID: 30674531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High macrophage PD-L1 expression not responsible for T cell suppression.
    Goldman N; Lomakova YD; Londregan J; Bucknum A; DePierri K; Somerville J; Riggs JE
    Cell Immunol; 2018 Feb; 324():50-58. PubMed ID: 29305065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
    Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
    Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHA eludes macrophage suppression to activate CD8
    Lomakova YD; Londregan J; Maslanka J; Goldman N; Somerville J; Riggs JE
    Immunobiology; 2019 Jan; 224(1):94-101. PubMed ID: 30446337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
    Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
    Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
    Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
    J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy.
    Clift R; Souratha J; Garrovillo SA; Zimmerman S; Blouw B
    Cancer Res; 2019 Aug; 79(16):4149-4159. PubMed ID: 31248966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors.
    Castiglioni A; Yang Y; Williams K; Gogineni A; Lane RS; Wang AW; Shyer JA; Zhang Z; Mittman S; Gutierrez A; Astarita JL; Thai M; Hung J; Yang YA; Pourmohamad T; Himmels P; De Simone M; Elstrott J; Capietto AH; Cubas R; Modrusan Z; Sandoval W; Ziai J; Gould SE; Fu W; Wang Y; Koerber JT; Sanjabi S; Mellman I; Turley SJ; Müller S
    Nat Commun; 2023 Aug; 14(1):4703. PubMed ID: 37543621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.
    Tan B; Shi X; Zhang J; Qin J; Zhang N; Ren H; Qian M; Siwko S; Carmon K; Liu Q; Han H; Du B; Liu M
    Cancer Res; 2018 Sep; 78(17):4929-4942. PubMed ID: 29967265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
    Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
    Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.